SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, including area code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange
on which registered
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|Item 7.01||Regulation FD Disclosure.|
On June 18, 2020, Sangamo Therapeutics, Inc. (“Sangamo”) issued a joint press release (the “Press Release”) with Pfizer Inc. (“Pfizer”) announcing updated follow-up data from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy in patients with severe hemophilia A (the “Alta Study”).
A copy of the Press Release is furnished hereto as Exhibit 99.1, and a copy of the slides containing updated follow-up data from the Alta Study that were presented at the World Federation of Hemophilia Virtual Summit on June 18, 2020 (the “Data Presentation”) is furnished hereto as Exhibit 99.2.
The information contained in this Item 7.01 and in the Press Release and the Data Presentation furnished as Exhibit 99.1 and Exhibit 99.2, respectively, to this current report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 and in the Press Release and Data Presentation furnished as Exhibit 99.1 and Exhibit 99.2, respectively, to this current report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Sangamo whether made before or after the date hereof, regardless of any general incorporation language in such filing.
The Press Release attached hereto as Exhibit 99.1 contains forward-looking statements regarding Sangamo’s current expectations. These forward-looking statements include, without limitation, statements relating to the potential to develop, obtain regulatory approvals for and commercialize SB-525 as a safe and effective therapy to treat hemophilia A, the potential long-term durability of SB-525 therapy, anticipated plans and timelines for conducting phase 3 clinical trials and sharing additional clinical data and other statements that are not historical fact. These statements are not guarantees of future performance and are subject to risks and uncertainties that are difficult to predict. Sangamo’s actual results may differ materially and adversely from those expressed. There can be no assurance that Sangamo will earn any additional milestone or royalty payments under the Pfizer collaboration. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to: the evolving COVID-19 pandemic and its impact on the global business environment, healthcare systems and the business and operations of Sangamo and Pfizer; the research and development process; the uncertain timing and unpredictable results of clinical trials, including whether final clinical trial data will validate the safety and efficacy of SB-525; the unpredictable regulatory approval process for product candidates across multiple regulatory authorities; the manufacturing of products and product candidates; the commercialization of approved products; the potential for technological developments that obviate technologies used by Sangamo and Pfizer in SB-525; the potential for Pfizer to terminate the SB-525 program or to breach or terminate its collaboration agreement with Sangamo; and the potential for Sangamo for fail to realize its expected benefits of its collaboration with Pfizer. These risks and uncertainties are described more fully in Sangamo’s filings with the U.S. Securities and Exchange Commission, including in its Quarterly Report on Form 10-Q for the quarter ended March 31, 2020. The information contained in the Press Release is as of June 18, 2020, and Sangamo undertakes no duty to update forward-looking statements contained in the Press Release except as required by applicable laws.
|Item 9.01||Financial Statements and Exhibits.|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SANGAMO THERAPEUTICS, INC.
Dated: June 18, 2020
Gary H. Loeb
Executive Vice President and General Counsel
|For Immediate Release||Pfizer Media Contact:||Steve Danehy|
|June 18, 2020||212-733-1538|
|Pfizer Investor Contact:||Chuck Triano|
|Sangamo Media Contact:||Aron Feingold|
|Sangamo Investor Contact:||McDavid Stilwell|
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy
Dosing of the first patient in the pivotal Phase 3 study anticipated in second half of 2020
New York, NY, and Brisbane, CA, June 18, 2020 Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec (SB-525, or PF-07055480), an investigational gene therapy for patients with severe hemophilia A. All five patients with severe hemophilia A who received the 3e13 vg/kg dose showed sustained factor VIII (FVIII) activity levels, with a median of 64.2% via chromogenic assay (patient-level geometric means after week 9 post-infusion). No patients experienced bleeding events or required FVIII infusions. The factor VIII activity levels reflect measurements up to 61 weeks, the extent of follow-up for the longest-treated patient in the cohort. These data are being presented today as a late-breaking oral abstract at the World Federation of Hemophilia 2020 World Congress, which is being held virtually from June 14 to June 19, 2020.
Giroctocogene fitelparvovec was generally well tolerated. As previously reported, one patient in the 3e13 vg/kg dose cohort had a treatment-related serious adverse event of hypotension (grade 3) and fever (grade 2), with symptoms of headache and tachycardia, which occurred six hours post-infusion with giroctocogene fitelparvovec, and which fully resolved within 24 hours. No other treatment-related serious adverse events were reported. Among the five patients in the 3e13 vg/kg dose cohort, four received corticosteroids for liver enzyme (alanine aminotransferase, ALT) elevations. Three patients had subsequent ALT elevations that responded to corticosteroids. All episodes of ALT elevations fully resolved with oral corticosteroids.
We are excited that these data affirm previous findings from this Phase 1/2 study, and that all five patients have sustained levels of factor VIII activity with no bleeding events or use of factor replacement therapy. We are encouraged by the potential of giroctocogene fitelparvovec to demonstrate longer-term durability, an important element for patients living with severe
hemophilia A, said Seng Cheng, Senior Vice President and Chief Scientific Officer of Pfizers Rare Disease Research Unit. The Phase 3 lead in study is ongoing, and we look forward to dosing patients with this investigational gene therapy in the pivotal Phase 3 trial later this year.
The current standard of care for severe hemophilia A requires regular infusions to replace missing Factor VIII. Gene therapy, on the other hand, offers a new approach with the potential to provide a one-time treatment that would enable patients to produce the missing factor on their own, said Bettina M. Cockroft, M.D., M.B.A., Chief Medical Officer of Sangamo. These follow-up data indicate that treatment with giroctocogene fitelparvovec resulted in sustained factor levels up to 14 months following treatment and suggests the potential of this investigational gene therapy to alleviate the treatment burden of current hemophilia disease management.
The additional follow-up builds on data presented at the 61st Annual Meeting of the American Society of Hematology (ASH) in December 2019, which demonstrated that giroctocogene fitelparvovec was generally well tolerated and resulted in sustained FVIII levels up to 44 weeks, the extent of follow-up for the longest-treated patient in the 3e13 vg/kg dose cohort at that time. The previously presented data included 11 patients treated across four ascending dose cohorts: 9e11 vg/kg (2 patients), 2e12 vg/kg (2 patients), 1e13 vg/kg (2 patients) and 3e13 vg/kg (5 patients). Pfizer and Sangamo plan to present further follow-up data from the Alta study when all five patients in the 3e13 vg/kg dose cohort have been followed for at least one year.
About the Alta study
The Phase 1/2 Alta study is an open-label, dose-ranging, multicenter clinical trial designed to assess the safety and tolerability of giroctocogene fitelparvovec in patients with severe hemophilia A. The mean age of the 11 patients assessed across four dose cohorts is 30 years (range 18-47 years). All 11 patients are male. The U.S. Food and Drug Administration has granted Orphan Drug, Fast Track, and regenerative medicine advanced therapy (RMAT) designations to giroctocogene fitelparvovec, which also received Orphan Medicinal Product designation from the European Medicines Agency. Giroctocogene fitelparvovec is being developed as part of a collaboration agreement for the global development and commercialization of gene therapies for hemophilia A between Sangamo and Pfizer.
About giroctocogene fitelparvovec
Giroctocogene fitelparvovec (SB-525 or PF-07055480), comprises a recombinant adeno-associated virus serotype 6 vector (AAV6) encoding the complementary deoxyribonucleic acid for B domain deleted human FVIII. The giroctocogene fitelparvovec expression cassette was designed for optimal liver-specific expression of FVIII protein and supports production of high yields of the vector. The giroctocogene fitelparvovec transcriptional cassette incorporates multi-factorial modifications to the liver-specific promoter module, FVIII transgene, synthetic polyadenylation signal and vector backbone sequence.
In late 2019, Sangamo transferred the manufacturing technology and the Investigational New Drug (IND) application to Pfizer. Pfizer is enrolling patients in the Phase 3 lead-in study (ClinicalTrials.gov Identifier: NCT03587116), the data from which is expected to provide a baseline for patients who are subsequently enrolled into the pivotal Phase 3 study (ClinicalTrials.gov Identifier: NCT04370054). The primary endpoint of the Phase 3 study is annualized bleeding rate (ABR) over 12 months, and secondary endpoints include steady state FVIII activity levels, annualized infusion rate of exogenous FVIII activity, annualized FVIII consumption, ABR and total ABR of specific type by cause and by location, and change in joint health using Hemophilia Joint Health Score, over 12 months.
About Sangamo Therapeutics
Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and gene regulation. For more information about Sangamo, visit www.sangamo.com.
About Pfizer Rare Disease
Rare diseases include some of the most serious of all illnesses and impact millions of patients worldwide, representing an opportunity to apply our knowledge and expertise to help make a significant impact on addressing unmet medical needs. The Pfizer focus on rare disease builds on more than two decades of experience, a dedicated research unit focusing on rare disease, and a global portfolio of multiple medicines within a number of disease areas of focus, including rare hematologic, neurologic, cardiac and inherited metabolic disorders.
Pfizer Rare Disease combines pioneering science and deep understanding of how diseases work with insights from innovative strategic collaborations with academic researchers, patients, and other companies to deliver transformative treatments and solutions. We innovate every day leveraging our global footprint to accelerate the development and delivery of groundbreaking medicines and the hope of cures.
Click here to learn more about our Rare Disease portfolio and how we empower patients, engage communities in our clinical development programs, and support programs that heighten disease awareness.
Pfizer Inc.: Breakthroughs that change patients lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the worlds premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com. In addition, to learn more, please visit us on www.pfizer.com and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
SANGAMO DISCLOSURE NOTICE:
This press release contains forward-looking statements regarding Sangamos current expectations. These forward-looking statements include, without limitation, statements relating to the potential to develop, obtain regulatory approvals for and commercialize SB-525 as a safe and effective therapy to treat hemophilia A, the potential long-term durability of SB-525 therapy, anticipated plans and timelines for conducting phase 3 clinical trials and sharing additional clinical data and other statements that are not historical fact. These statements are not guarantees of future performance and are subject to risks and uncertainties that are difficult to predict. Sangamos actual results may differ materially and adversely from those expressed. There can be no assurance that Sangamo will earn any additional milestone or royalty payments under the Pfizer collaboration. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to: the evolving COVID-19 pandemic and its impact on the global business environment, healthcare systems and the business and operations of Sangamo and Pfizer; the research and development process; the uncertain timing and unpredictable results of clinical trials, including whether final clinical trial data will validate the safety and efficacy of SB-525; the unpredictable regulatory approval process for product candidates across multiple regulatory authorities; the manufacturing of products and product candidates; the commercialization of approved products; the potential for
technological developments that obviate technologies used by Sangamo and Pfizer in SB-525; the potential for Pfizer to terminate the SB-525 program or to breach or terminate its collaboration agreement with Sangamo; and the potential for Sangamo for fail to realize its expected benefits of its collaboration with Pfizer. These risks and uncertainties are described more fully in Sangamos filings with the U.S. Securities and Exchange Commission, including its most recent Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 and Annual Report on Form 10-K for the year ended December 31, 2019. The information contained in this release is as of June 18, 2020, and Sangamo undertakes no duty to update forward-looking statements contained in this release except as required by applicable laws.
PFIZER DISCLOSURE NOTICE:
The information contained in this release is as of June 18, 2020. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
This release contains forward-looking information about an investigational hemophilia A therapy, giroctocogene fitelparvovec (SB-525, or PF-07055480), including its potential benefits and the anticipated timing of a phase 3 clinical trial, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; risks associated with interim data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when drug applications for any potential indications for giroctocogene fitelparvovec may be filed in any jurisdictions; whether and when regulatory authorities in any jurisdictions may approve any such applications, which will depend on myriad factors, including making a determination as to whether the products benefits outweigh its known risks and determination of the products efficacy and, if approved, whether giroctocogene fitelparvovec will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of giroctocogene fitelparvovec; uncertainties regarding the impact of COVID-19 on Pfizers business, operations and financial results; and competitive developments.
A further description of risks and uncertainties can be found in Pfizers Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned Risk Factors and Forward-Looking Information and Factors That May Affect Future Results, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.
Updated Follow-up of the High-Dose Cohort in the Alta Study, a Phase 1/2 Study of giroctocogene fitelparvovec (SB-525) Gene Therapy in Adults With Severe Hemophilia A Thomas J. Harrington, MD1; Barbara A. Konkle, MD2; Kimo Stine, MD3; Nathan Visweshwar, MD4; Andrew D. Leavitt, MD5; Adam Giermasz, MD, PhD6; Steven Arkin, MD7; Annie Fang, MD, PhD8; Li-Jung Tseng, MBA, PhD8; Gregory Di Russo, MD7; Bettina M.Cockroft, MD, MBA9; Adrian Woolfson, MD, PhD9; Jeremy Rupon, MD, PhD10; Didier Rouy, MD, PhD9 1University of Miami Miller School of Medicine, Miami, FL, USA; 2Bloodworks Northwest and the University of Washington, Seattle, WA, USA; 3UAMS at Arkansas Children’s Hospital, Little Rock, AR, USA; 4University of South Florida, Tampa, FL, USA; 5University of California, San Francisco, CA; 6University of California Davis, Sacramento, CA, USA; 7Pfizer Inc, Cambridge, MA, USA; 8Pfizer Inc, New York, NY, USA; 9Sangamo Therapeutics, Brisbane, CA, USA; 10Pfizer Inc, Collegeville, PA, USA Presented at the World Federation of Hemophilia (WFH) Virtual Summit, June 14–19, 2020 Exhibit 99.2
Disclosures for: Thomas J. Harrington, MD Conflict Disclosure Research Support Sangamo/Pfizer Inc. Director, Officer, Employee none Shareholder none Honoraria none Advisory Committee none Consultant none
Data in this presentation are presented “as-is” and potentially subject to change. Disclaimer
Characterized by increased bleeding caused by low levels of factor VIII (FVIII) activity resulting from mutations in the F8 gene Treatment is currently based on replacement therapy with exogenous FVIII, along with emerging mimetic-based therapy Current treatments require frequent dosing to be effective, and involve intravenous (IV) or subcutaneous administration Maintenance of FVIII activity in the mild to normal range can improve the outcomes for patients with hemophilia A The wide therapeutic window and underlying single gene defect make hemophilia A an ideal candidate for gene therapy Hemophilia A
Giroctocogene fitelparvovec (SB-525) Gene Therapy for Hemophilia A Alta is a phase 1/2 dose-ranging, single-dose, multicenter study to assess the safety and tolerability of giroctocogene fitelparvovec (SB-525) in adult subjects (aged ≥18 years) with severe hemophilia A Giroctocogene fitelparvovec (SB-525) is a liver-tropic recombinant adeno-associated virus (rAAV6) vector carrying a B-domain–deleted F8 gene that is delivered through a single IV infusion Key exclusion criteria Neutralizing activity to AAV6 capsid and/or inhibitor to FVIII History of hypersensitivity response to FVIII replacement therapy History of liver dysfunction Contraindication to steroids
Study End Points Primary end points Safety and tolerability of SB-525, as assessed by the incidence of adverse events (AEs) and serious adverse events (SAEs) and by changes in clinical laboratory assessments, vital signs and electrocardiogram, and liver imaging Changes in circulating FVIII activity Secondary end points Change from baseline in the use of FVIII replacement therapy and frequency and severity of bleeding episodes Measurement of FVIII inhibitor levels Vector shedding in bodily fluids
Study Status 4 dose cohorts of 2 subjects each and a high-dose cohort expansion of 3 subjects (total of 11 subjects dosed); no prophylactic steroid use Steroid treatment is initiated for alanine aminotransferase (ALT) elevation that exceeds 1.5x baseline value The safety and efficacy data of each cohort were reviewed by an independent safety monitoring committee prior to each dose escalation and prior to initiating cohort 4 expansion
Min-max, minimum-maximum. Data cut: March 2020 Patient Demographics Characteristic Cohort 1 9e11 vg/kg Cohort 2 2e12 vg/kg Cohort 3 1e13 vg/kg Cohort 4 3e13 vg/kg All Subjects Age, years n 2 2 2 5 11 Mean (SD) 30.5 (9.19) 35.5 (16.26) 32.0 (1.41) 26.8 (6.30) 30.0 (7.94) Median 30.5 35.5 32.0 29.0 30.0 Min-max 24, 37 24, 47 31, 33 18, 34 18, 47 Gender, n (%) Male 2 (100) 2 (100) 2 (100) 5 (100) 11 (100) Race, n (%) Asian – 1 (50) – – 1 (9.1) White 2 (100) 1 (50) 2 (100) 4 (80.0) 9 (81.8) Other – – – 1 (20.0) 1 (9.1) Ethnicity, n (%) Hispanic or Latino – – – 2 (40.0) 2 (18.2) Not Hispanic or Latino 2 (100) 2 (100) 2 (100) 3 (60.0) 9 (81.8) Study Status, cont’d
Safety Summary: Cohort 4 (3x1013 vg/kg) 1 subject had a treatment-related serious adverse event (SAE) of grade 3 hypotension and grade 2 fever, with symptoms of headache and tachycardia occurring ≈6 hours after completion of the vector infusion, with resolution ≈12 hours postinfusion No additional treatment-related SAEs 4/5 subjects in the high dose cohort required corticosteroid treatment for elevations in liver transaminase (ALT/AST), which all resolved with intervention 3 of the 4 subjects had subsequent elevations in liver transaminases after resolution of the initial increase and received a repeat course of corticosteroids, which all resulted in resolution Efficacious FVIII activity levels were maintained in all cases
Safety Summary: Treatment-Related Adverse Events Cohort 4 (3x1013 vg/kg) MedDRA Preferred Term Cohort 4 3e13 vg/kg (N=5) Subjects, n (%) No. of Events Any treatment-related event 5 (100.0) 42 Alanine aminotransferase increased* 3 (60.0) 9 Pyrexia 4 (80.0) 4 Aspartate aminotransferase increased 1 (20.0) 2 Tachycardia 2 (40.0) 2 Fatigue 1 (20.0) 1 Hypotension 1 (20.0) 1 Myalgia 1 (20.0) 1 *One subject had an ALT increase as per central lab results, but Investigator has not reported increase as an Adverse Event Data cut: March 2020
ALT Elevations: Cohort 4 (3x1013 vg/kg) Subject ID Number Time of First ALT Elevation (Week) Maximum ALT Value, U/L (Grade) Steroids, >60mg (Weeks) Steroids, Taper (Weeks) FVIII levels (Chromo, IU/dL) at Start of Steroids FVIII Levels (Chromo, IU/dl) at End of Taper Time of Second ALT Elevation (Week) Weeks of Steroids After Second Elevation 7 4.5 91 (gr 1) 3 11 94.8 108.2 48# 16# 8 12 66 (gr 1) 1 16 83.1 112.6 N/A N/A 10 5.5 63 (gr 1) N/A* 6 46.4 57.1 20 9 11 8 192 (gr 2) 1.5 4 80.2 27.7 16 18 4 of 5 subjects in cohort 4 had an ALT elevation N/A: not applicable *: Subject started at 60mg. #: Subject had an additional isolated elevation of ALT at week 28 that was treated with corticosteroids for 1 week and then discontinued. Treatment was ongoing at the time of data cut. Data cut March 2020
Efficacy: Cohort 4 (3x1013 vg/kg) Latest available FVIII values from March 2020 data cut FVIII Activity as measured at Central Laboratory with Chromogenic Assay
Efficacy: Cohort 4 (3x1013 vg/kg) N=5 Patients (Up to Wk 28) N=4 (Up to Wk 36) 50% Factor VIII activity (Lower bound of Normal) Study Week Mean Factor VIII activity value from Week 9 to Week 36 (based on group mean) * Mean (Box-Whisker plot) Data cut: March 2020
Efficacy: Cohort 4 (3x1013 vg/kg) Steady-state FVIII activity achieved by week 9 post infusion Subjects have been followed for 33-65 weeks, FVIII activity values available up to week 30 and up to week 61 Median steady-state (of geometric means since week 9) FVIII activity level 64.2% via central laboratory chromogenic assay (CA; previously reported that CA tends to correlate better with FVIII antigen level than one-stage clotting assay (OS)) No bleeding events No FVIII infusions beyond initial use of prophylactic factor
Conclusions Cohort 4 (3x1013 vg/kg): With follow-up ranging 33 to 65 weeks, data continues to show that giroctocogene fitelparvovec (SB-525) is generally well tolerated Sustained FVIII activity levels in the mild to normal range No use of exogenous FVIII beyond week 3 post infusion No bleeding events 1 treatment related SAE during vector infusion, no additional treatment related SAEs Follow-up for Cohorts 1-3 extends up to over 2 years with no safety signals The Ph1/2 study is ongoing and supports further development of giroctocogene fitelparvovec (SB-525) Phase 3 lead-in study is ongoing